InfuSystem Holdings Inc. (INFU) Insider Trading

Last 12 months

Insiders bought $150k on the open market and sold nothing.

Net open-market

+$150k

4 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

3 / 0

executives and directors

Last open-market buy

May 2026

May 11, 2026

Get an email when INFU's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 8 – 11	Carrie Lachance President and CEO	Bought 2 parts	3,000	$8.71 average	$26k	1.3%	Form 4
May 8	Paul Andrew Gendron Director	Bought	5,000	$8.88	$44k	7.7%	Form 4
May 8	Barry G Steele Executive VP and CFO	Bought	7,000	$8.71	$61k	7.8%	Form 4
Mar 2	Barry G Steele Executive VP and CFO	Bought	2,064	$9.16	$19k	2.4%	Form 4
Aug 22, 2025	Scott Shuda Director	SoldNo plan	5,752	$9.67	$56k	1.4%	Form 4
May 28, 2025	Kenneth D. Eichenbaum Director	Bought	2,000	$5.18	$10k	50%	Form 4
May 19, 2025	Ronald T Hundzinski Director	Bought	5,000	$6.09	$30k	New	Form 4
May 15, 2025 – May 16, 2025	Carrie Lachance President and COO	Bought 2 parts	3,132	$6.07 average	$19k	1.7%	Form 4
May 14, 2025	Barry G Steele Executive VP and CFO	Bought	3,000	$5.76	$17k	4.1%	Form 4
Nov 25, 2024 – Nov 27, 2024	Richard Dilorio Chief Executive Officer	Sold10b5-1 plan 3 parts	40,000	$9.11 average	$364k	8.8%	Form 4

May 8 – 11
Carrie Lachance
President and CEO · bought 3,000 at avg $8.71
$26k
1.3% of stake
May 8
Paul Andrew Gendron
Director · bought 5,000 at $8.88
$44k
7.7% of stake
May 8
Barry G Steele
Executive VP and CFO · bought 7,000 at $8.71
$61k
7.8% of stake
Mar 2
Barry G Steele
Executive VP and CFO · bought 2,064 at $9.16
$19k
2.4% of stake
Aug 22, 2025No plan
Scott Shuda
Director · sold 5,752 at $9.67
$56k
1.4% of stake
May 28, 2025
Kenneth D. Eichenbaum
Director · bought 2,000 at $5.18
$10k
50% of stake
May 19, 2025
Ronald T Hundzinski
Director · bought 5,000 at $6.09
$30k
New position
May 15, 2025 – May 16, 2025
Carrie Lachance
President and COO · bought 3,132 at avg $6.07
$19k
1.7% of stake
May 14, 2025
Barry G Steele
Executive VP and CFO · bought 3,000 at $5.76
$17k
4.1% of stake
Nov 25, 2024 – Nov 27, 202410b5-1 plan
Richard Dilorio
Chief Executive Officer · sold 40,000 at avg $9.11
$364k
8.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch INFU, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

STIMNeuronetics Inc.

ANIKAnika Therapeutics Inc.

BBNXBeta Bionics Inc.

OSUROrasure Technologies Inc.

XTNTXtant Medical Holdings Inc.

KMTSKestra Medical Technologies, Ltd.

NPCENeuroPace Inc.

MHUAFMeihua International Medical Technologies Co., Ltd.

Spot a number that looks wrong? Check it in INFU's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing INFU

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.